Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: A meta-analysis of randomized trials

Vaccine

Volumn 32, Issue 39, 2014, Pages 4885-4892

  da Costa, Vivaldo G ^a   Marques Silva, Ariany C ^a   Floriano, Vitor G ^a   Moreli, Marcos L ^a  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

Author keywords

CYD TDV; Dengue vaccine; Efficacy; Immunogenicity; Meta analysis; Safety

Indexed keywords

DENGUE VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT TETRAVALENT DENGUE VACCINE; UNCLASSIFIED DRUG; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ALLERGIC REACTION; CLINICAL TRIAL; DENGUE; DRUG SAFETY; ERYTHEMA; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALAISE; META ANALYSIS; MYALGIA; PAIN; PRIORITY JOURNAL; REVIEW; SWELLING; UNSPECIFIED SIDE EFFECT; BLOOD; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); THEORETICAL MODEL;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DENGUE; DENGUE VACCINES; HUMANS; MODELS, THEORETICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINES, SYNTHETIC;

EID: 84906100009     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.008     Document Type: Review

References (56)

1. Guzman M.G., Halstead S.B., Artsob H., Buchy P., Farrar J., Gubler D.J., et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8(Suppl):s7-s16.
2. Shepard D.S., Undurraga E.A., Halasa Y.A. Economic and disease burden of dengue in southeast Asia. PLoS Negl Trop Dis 2013, 7:e2055.
3. World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control 2009. Available at http://www.who.int/tdr/publications/documents/dengue diagnosis.pdf
4. Lopes A.D., Mathers C.D., Ezzati M., Jamison D.T., Murray C.J. Global burden of disease and risk factors 2006, Oxford University Press, Oxford.
5. Holmes E.C., Burch S.S. The causes and consequences of genetic variation in dengue virus. Trends Microbiol 2000, 8:74-77.
6. Monath T.P., Tsai T.F. Flaviviruses. Clinical virology 2000, 1133-1179. Churchill Livingstone Inc., New York, NY. D.D. Richman, R.J. Whitley, F.G. Hayden (Eds.).
7. Halstead S.B. Dengue. Lancet 2007, 370:1644-1652.
8. Murphy B.R., Whitehead S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
9. Whitehead S.S., Blaney J.E., Durbin A.P., Murphy B.R. Prospects for a dengue virus vaccine. Nat Rev Microbiol 2007, 5:518-528.
10. Durbin A.P., Whitehead S.S. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011, 3:800-814. 10.3390/v3101800.
11. McArthur M.A., Sztein M.B., Edelman R. Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines 2013, 12:933-953.
12. Zellweger R.M., Miller R., Eddy W.E., White L.J., Johnston R.E., Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013, 9:e1003723. 10.1371/journal.ppat.1003723.
13. del Angel R.M., Reyes-del V.J. Dengue vaccines: strongly sought but not a reality just yet. PLoS Pathog 2013, 9:e1003551. 10.1371/journal.ppat.1003551.
14. Torresi J., Tapia-Conyer R., Margolis H. Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V international meeting. PLoS Negl Trop Dis 2013, 7:e2261. 10.1371/journal.pntd.0002261.
15. Züst R., Dong H., Li X.F., Chang B., Balakrishnan T., Toh Y.X., Jiang T., et al. Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques. PLoS Pathog 2013, 9:e1003521. 10.1371/journal.ppat.1003521.
16. Huang C.Y., Kinney R.M., Livengood J.A., Bolling B., Arguelo J.J., Luy B.E., et al. Genetic and phenotypic characterization of manufacturing seeds for a tetravalent dengue vaccine (DENVax). PLoS Negl Trop Dis 2013, 7:e2243. 10.1371/journal.pntd.0002243.
17. Zhao H., Jiang T., Zhou X.Z., Deng Y.Q., Li X.F., Chen S.P., et al. Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine. PLoS One 2014, 9:e86573. 10.1371/journal.pone.0086573.
18. Azevedo A.S., Yamamura A.M., Freire M.S., Trindade G.F., Bonaldo M., Galler R., Alves A.M. DNA vaccines against dengue vírus type 2 based on truncate envelope protein or its domain III. PLoS One 2011, 6:e20528. 10.1371/journal.pone.0020528.
19. Azevedo A.S., Gonçalves A.J., Archer M., Freire M.S., Galler R., Alves A.M. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue. PLoS One 2013, 8:e58357. 10.1371/journal.pone.0058357.
20. Guy B., Barrere B., Malinowski C., Saville M., Teyssou R., Lang J. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011, 29:7229-7241.
21. Thomas S.J., Eckels K.H., Carletti I., Barrera R.D.L., Dessy F., Fernandez S., et al. A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults. Am J Trop Med Hyg 2013, 88:73-88.
22. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009, 339:332-336.
23. Cappuccio F.P., Kerry S.M., Forbes L., Donald A. Blood pressure control by home monitoring: meta-analysis of randomized trials. BMJ 2004, 329:145-148.
24. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
25. Thompson S.G., Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 1999, 18:2693-2708.
26. Sterne J.A., Egger M., Smith D.G. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001, 323:101-105.
27. Thompson S.G. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994, 309:1351-1355.
28. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
29. Lau J., Ioannidis J.P., Terrin N., Schmid C.H., Olkin I. The case of the misleading funnel plot. BMJ 2006, 333:597-600.
30. Jadad A.R., Moore R.A., Caroll D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., McQuay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control Clin Trials 1996, 17:1-12.
31. Harris R.J., Bradburn M.J., Deeks J.J., Harbord R.M., Altman D.G., Sterne J.A.C. Metan: fixed- and random-effects meta-analysis. Stata J 2008, 8:3-28.
32. Morrison D., Legg T.J., Billings C.W., Forrat R., Yoksan S., Lang J. A novel a tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in Flavivirus-naive adults. J Infect Dis 2010, 201:370-377.
33. Guy B., Nougarede N., Begue S., Sanchez V., Souag N., Carre M., et al. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 2008, 26:5712-5721.
34. Guy B., Saville M., Lang J. Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccines 2010, 6:696-705.
35. Qiao M., Shaw D., Forrat R., Wartel-Tram A., Lang J. Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans. Am J Trop Med Hyg 2011, 85:724-731.
36. Poo J., Galan F., Forrat R., Zambrano B., Lang J., Dayan G.H. Live-attenuated tetravalent dengue vaccine in dengue-naïve children, adolescents, and adults in Mexico City. Pediatr Infect Dis J 2011, 30:e9-e17.
37. Capeding R.Z., Luna I.A., Bomasang E., Lupisan S., Lang J., Forrat R., et al. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 2011, 29:3863-3872.
38. Dayan G.H., Thakur M., Boaz M., Johnson C. Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 2013, 31:5047-5054.
39. Dayan G.H., Garbes P., Noriega F., Sadovsky A.D.I., Rodrigues P.M., Giuberti C., Dietze R. Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil. Am J Trop Med Hyg 2013, 89:1058-1065.
40. Amar-Singh H.S.S., Koh M.T., Tan K.K., Chan L.G., Zhou L., Bouckenooghe A., et al. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled phase III study. Vaccine 2013, 31:5814-5821.
41. Villar L.A., Rivera-Medina D.M., Arredondo-García J.L., Boaz M., Starr-Spires L., Thakur M., et al. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds. A randomized, controlled, phase II trial in Latin America. Pediatr Infect Dis J 2013, 32:1102-1109.
42. Leo Y.S., Wilder-Smith A., Archuleta S., Shek L.P., Chong C.Y., Leong H.N., et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 years--Phase II randomized controlled trial in Singapore. Hum Vaccines Immunother 2012, 8:1259-1271.
43. Tran N.H., Luong C.Q., Vu T.Q.H., Forrat R., Lang J., Vu Q.D., et al. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD-TDV) in healthy Vietnamese adults and children. J Vaccines Vaccin 2012, 3:162. 10.4172/2157-7560.1000162.
44. Lanata C.F., Andrade T., Gil A.I., Terrones C., Valladolid O., Zambrano B., et al. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru. Vaccine 2012, 30:5935-5941.
45. Sabchareon A., Wallace D., Sirivichayakul C., Limkittikul K., Chanthavanich P., Suvannadabba S., et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase IIb trial. Lancet 2012, 380:1559-1567.
46. Hombach J., Cardosa M.J., Sabchareon A., Vaughn D.W., Barrett A.D. Scientific consultation on immunological correlates of protection induced by dengue vaccines report from meeting held at the World Health Organization 17-18 November 2005. Vaccine 2007, 25:4130-4139.
47. Thomas S.J. The necessity and quandaries of dengue vaccine development. J Infect Dis 2011, 203:299-303.
48. Thomas S.J., Endy T.P. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011, 24:442-450.
49. Roehrig J.T., Hombach J., Barrett A.D. Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Virol Immunol 2008, 21:123-132.
50. Halstead S.B. Identifying protective dengue vaccines: guide to mastering an empirical process. Vaccine 2013, 31:4501-4507.
51. Sirivichayakul C., Sabchareon A., Limkittikul K., Yokasan S. Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand. Virol J 2014, 11:48. 10.1186/1743-422X-11-48.
52. Mammen M.P., Lyons A., Innis B.L., Sun W., McKinney D., Chung R.C.Y., et al. Evaluation of dengue virus strains for human challenge studies. Vaccine 2014, 32:1488-1494.
53. Rodriguez-Barraquer I., Teran-Romero L.M., Burke D.S., Cummings D.A.T. Challenges in the interpretation of dengue vaccine trial results. PLoS Negl Trop Dis 2013, 7:e2126. 10.1371/journal.pntd.0002126.
54. Endy T.P., Anderson K.B., Nisalak A., Yoon I.K., Green S., Rothman A.L., et al. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. PLoS Negl Trop Dis 2011, 1:e975. 10.1371/journal.pntd.0000975.
55. Bancroft W.H., Top F.H., Eckels K.H., Anderson J.H., McCown J.M., Russell P.K. Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients. Infect Immun 1981, 31:698-703.
56. Mansfield K.L., Horton D.L., Johnson N., Li L., Barrett A.D.T., Smith D.J., et al. Flavivirus-induced antibody cross-reactivity. J Gen Virol 2011, 92:2821-2829.